Many mature individuals with weight problems or individuals with chelation requirements for cardiovascular disorders have components of the Metabolic Syndrome X. Syndrome X affects about 70 million Americans. Syndrome X is the variable combination of obesity, abnormal blood cholesterol (dyslipidemia) and high blood pressure, linked by underlying resistance to the hormone insulin. Multipronged, synergistic, metabolic
and lifestyle approaches are required to combat the multiple components of Syndrome X. Some of the components of Syndrome X may require appropriate drug treatments.
Syndrome X is often associated with excessive secretion of insulin. The syndrome was first described by Reaven in 1998, but its principal component of obesity was not initially emphasized. Retrospective data from the National Health Nutritional Survey, for the period 1988 to 1994, implied that 47-million Americans had Metabolic Syndrome. The current prevalence of Syndrome X may now be one in every four or five adults
in the United States population. So common and so pernicious are the negative health outcomes of Metabolic Syndrome X that it qualifies as the number-one public health problem facing several Western societies.
Although the Metabolic Syndrome X is identified as a major cause of cardiovascular disease, it is less apparent that it increases deaths and disabilities from all causes, and it underlies female reproductive disorders, polycystic ovary syndrome (PCOS), non-alcoholic fatty-liver disease, non-alcoholic steatohepatitis, gestational diabetes mellitus, significant changes in body eicosanoid status (inflammation), impaired immunity,
Alzheimer’s disease and certain cancers. This is the concept of Syndrome X, Y and Z...(Holt, 2000)
The influence of eicosanoids on glucose and insulin homeostasis has been defined partially, but the influence of insulin resistance, (or lack) on eicosanoid pathways is not clear. Many individuals with Syndrome X have a dietary status where eicosanoid pathways are driven towards the production of prothrombotic and pro-inflammatory prostaglandins. This may occur largely as a consequence of dietary deficiency of certain
essential fatty acids (Omega-3) or alteration in the ratio of omega 6 and omega 3 essential fatty acid, dietary intake. Furthermore, there is evidence that eicosanoid production can be modified by insulin lack and hyperglycemia (see CLINICAL EPA/DHA FORTE™).
Animal studies show increases in a circulating metabolites of PGE2 production after the experimental induction of diabetes with streptozotocin. This rise in PGE2 metabolites is also found in diabetic humans. Thus, both of these circumstances can contribute to the development of Syndrome X and insulin resistance. Within the metabolic Syndrome X, one may expect to cause changes in the body eicosanoid status in a detrimental manner for health. This metabolic change in eicosanoid status is mainly a quantitative difference in the types of eicosanoid (prostaglandins) produced. More important, it is known that among eicosanoid derivatives, eicosapentanoic acid (EPA) can enhance insulin sensitivity, presumably through effects on PPAR-receptors, which regulate the actions of insulin and cholesterol metabolism (see CLINICAL EPA/ DHA FORTE™).
These observations open a pathway to the development of nutraceutical combinations tailored to specifically affect the function of the human genomic control of cell functions--or“genome-directed nutraceuticals.” In this context, some recent and highly popular diets for weight control require reappraisal.
Diets intended to combat the syndrome should have more liberal contents of omega-3 fatty acids, in the correct balance of omega-3 and 6 with one another, together with a strictly controlled intake of refined carbohydrates, a restricted salt intake, an optimal intake of fiber intake, and an increased proportion of vegetable sources of protein. Low carbohydrate diets require facilitation to make them more effective in the long term and more healthy in terms of the global initiative of healthy weight control, with lowering of cholesterol, blood pressure and combat against insulin resistance. Clinical Metabolic Syndrome X Nutritional Factors™ have versatile applications in wellness promotion. How often do you diagnose Syndrome X?
64 Nutritional Support Pathways for the Natural Clinician NOTES ON METABOLIC SYNDROME X NUTRITIONAL FACTORS™ (not treatment claims)
Insulin resistance may be addressed chromium polynicotinate, vanadium, maitake, green tea polyphenols, mixed berry antioxidants and alpha lipoic. Beta-glucan fractions of oat soluble fiber may lower blood glucose levels after sugar intake. Green coffee bean extracts alter hepatic glucose metabolism. Cinnamon is an insulin mimetic. Abnormal blood lipids benefit in nutritional support with antioxidants and chromium with (biotin) may exert favorable effects on blood cholesterol. Oat beta-glucan may reduce blood levels of lowdensity lipoprotein (LDL) cholesterol, and triglycerides; and it may variably increase high-density lipoprotein (HDL) cholesterol. Obesity--Starch-blockers may inhibit sugar absorption.
Oat beta-glucan may produce a sensation of satiety when taken before meals, and thereby assist in controlling calorie intake. Delayed appetite suppressant effects of fiber occur and smoothing out blood glucose responses may help to stop“sugar craving.” Variable but small reductions in blood pressure result from weight control and lifestyle changes, e.g. exercise, avoidance of substance abuse (alcohol, caffeine and smoking). Soluble fiber may have modest independent blood pressure- lowering effects.Oxidative stress and advanced glycation end products may respond to antioxidants. This may occur with bioflavonoids, ellagic acid, anthocyanidins, alpha lipoic acid and other antioxidants. Homocysteine--Vitamins B6, B12, and folic acid may reduce blood homocysteine levels. Homocysteine and hyperuricemia must not be overlooked in the Metabolic Syndrome X.
Syndrome X Nutritional Factors™ powder contains: Patented glucolloid, beta glucan fraction of oat soluble fiber (7.5g), Chromium polynicotinate (500mcg), Biotin (250mcg), a proprietary blend of alpha lipoic acid, guar gum and white kidney bean extract (850mg), Vitamin B6 (2mg), Folic acid (400mcg), Vitamin B12 (6mcg) and Vanadium (50mcg). ADVANTRA Z 65
Syndrome X Nutritional Factors™ capsules contains: Fish Oil Fatty Acids (in variable formulations 375mg), Maitake Mushroom (225mg), Citrus Bioflavanoids Complex (180mg), Green Tea 50% Polyphenols (150mg), Oat Bran 10% (Beta Glucans (150mg), Berry Supreme Blend (150mg), Cinnamon Bark (100mg), Kidney Bean Extract (Phase 2 Starch Neutralizer), Alpha Lipoic Acid (37.5mg), Green Coffee Bean 50% Chlorogenic Acid (30mg), Pomegranate Fruit 90% Ellagic Acid (22.5mg), Grape Seed 95%(OPC’s) (22.5mg), Zinc (Amino Acid Chelate) (15mg), Vitamin B6 (Pyridoxine HCI) (2mg), Folic Acid (400mcg), Chromium (Polynicotinate, ChromeMate) (360mg), Biotin (300mcg), Vanadium(Amino Acid Chelate)(15mcg) and Vitamin B12 (Cyanocobalamin), in variable formulations.